LOTTE (004990) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
23 Jun, 2026Executive summary
Revenue for 2Q25 was KRW 4,043 billion, down 1.6% year-over-year; operating profit fell 13.9% to KRW 142 billion, mainly due to raw material cost pressures despite strong global F&B sales.
Net loss narrowed to KRW 69 billion from KRW 147 billion in 2Q24, reflecting improved performance in some subsidiaries and reduced one-off losses.
Financial highlights
Consolidated revenue for H1 2025 was KRW 15.76 trillion, with operating income of KRW 160.2 billion, and a net loss of KRW 160.4 billion, reflecting a challenging environment compared to prior years.
1H25 consolidated revenue was KRW 7,628 billion, down 2.8% year-over-year; operating profit dropped 31.7% to KRW 160 billion.
F&B division 2Q25 revenue grew 1.4% year-over-year to KRW 2,452 billion, but operating profit declined 16.6% to KRW 113 billion due to higher cocoa prices and one-off costs.
Retail (Korea Seven) saw 2Q25 revenue fall 9.5% year-over-year to KRW 1,255 billion, with operating losses narrowing to KRW 8 billion.
Other businesses posted a 4.1% year-over-year revenue increase to KRW 512 billion and a 282.9% surge in operating profit to KRW 17 billion in 2Q25.
Outlook and guidance
F&B companies expect improved earnings in 2H25, supported by consumption coupons, favorable weather, and stabilizing raw material prices.
Retail expects a favorable business environment in 2H25 due to government consumption coupons and weather conditions.
Management continues to focus on cost control, portfolio optimization, and ESG initiatives, with a target to reduce plastic use and carbon emissions.
The group aims to maintain a dividend payout ratio above 35% and is considering further treasury share cancellations to enhance shareholder value.
Ongoing expansion in overseas markets, especially in Southeast Asia, and continued investment in specialty chemicals and advanced materials.
Latest events from LOTTE
- H1 2024 saw record revenue but a net loss due to equity losses and chemical headwinds.004990
Q2 202423 Jun 2026 - Record revenue but net loss due to cost pressures; major biologics investments continue.004990
Q3 202423 Jun 2026 - Revenue fell 4.1% YoY to KRW 3.59 trillion, with a net loss of KRW 91.87 billion.004990
Q1 202523 Jun 2026 - 3Q25 revenue was KRW 4,154B, with a net loss of KRW -283.9B and a 156.1% debt ratio.004990
Q3 202523 Jun 2026 - Operating profit surged 156% year-over-year as F&B growth offset retail restructuring.004990
Q1 202622 Jun 2026 - 4Q25 saw stable revenue, wider operating loss, improved net loss, and higher shareholder returns.004990
Q4 202529 Mar 2026 - Targeting 35%+ shareholder return rate and growth via new businesses and ESG leadership.004990
Corporate Value-up Plan presentation15 Jan 2026 - Record sales offset by profit decline from higher costs and affiliate losses; growth plans continue.004990
Q4 202415 Jan 2026 - Pursuing balanced growth via restructuring, global expansion, and new growth investments.004990
IR Day presentation15 Jan 2026